INTRODUCTION AND OBJECTIVES: It is generally accepted that Peyronie 0 s disease (PD) is more common in Caucasian (CA) males than it is in African-American (AA) males. Differences in wound healing have been noted between CA and AA men; however, the racial variation between CA and AA men with PD who undergo intralesional collagenase clostridium histolyticum (CCH) treatment remains unclear. The objective of this study was to determine if race has an impact on response to intralesional CCH.
METHODS: We conducted a retrospective medical chart review at our institution of the records of all patients treated with CCH for PD between 04/2014 and 01/2016. Collected variables included demographics, including age and race, sexual function, penile curvature, and treatment outcomes. The primary outcome was a significant (!20%) decrease in penile curvature over baseline at the conclusion of treatment.
RESULTS: The retrospective chart review yielded 76 total patients who underwent CCH therapy for PD. Out of these patients, 66 designated themselves as CA and 5 designated themselves as AA. The remaining 4 patients designated themselves as 00 other 00 and were excluded from the analysis. A significant difference between racial groups was duration of PD, which was shorter for AA patients at an average of 5.4AE4.45 months duration compared to an average of 30.5AE63.1 months duration in CA patients (p¼0.0025). AA men experienced an average curvature improvement of 9.0AE6.52 versus 16.3AE13.2(p¼0.066). There were no significant differences between patients of different races in age, IIEF values both before and after treatment, penile length, or penile circumference.
CONCLUSIONS: While the PD patient population is predominantly CA, the difference in response between AA and CA trended towards statistical significance. Further studies with larger databases are needed to determine if there are differences in response to CCH between these two groups. METHODS: We conducted a retrospective review of the records for all patients treated with CCH for PD between 04/2014 and 03/ 2016. Patients qualified as being in the acute phase of PD if they reported penile pain and duration of PD < 12 months at presentation. The primary outcomes of interest were final change in curvature after CCH treatment regardless of number of CCH cycles received, and frequency of treatment-related adverse events (TRAE). Paired t-Test and Chisquared tests were performed to determine statistical significance (P<0.05).
Source of Funding: None
RESULTS: A total of 77 patients were included in the study, of which 21 (27%) qualified as acute phase PD and the remaining 56 (73%) as stable phase. Median duration of PD was 8 months for acute phase patients, and 21 months for stable phase (p¼0.033). There was no significant difference in final change in curvature between the acute and stable phase of PD (16.2 vs. 14.9 , p¼0.702). There was a significant difference in change in curvature reported after the first cycle of treatment between the acute and stable phase (21.7 vs. 12.5 , p¼0.037). There was no statistically significant difference in frequency of TRAEs between the acute phase (3, 14%) and the stable phase (4, 7%) (p¼0.332).
CONCLUSIONS: Although CCH is currently contraindicated during the acute phase of PD, preliminary results suggest that CCH use during this setting may be both effective and safe. There was no statistically significant difference in final change in curvature or TRAEs after CCH therapy between the acute and stable phase of PD. METHODS: We conducted a retrospective review of the records for a cohort of collagenase patients treated with CCH for PD between 04/2014 and 03/2016 who underwent penile duplex Doppler ultrasound (PDDU) after pharmacologically induced erection both before and after CCH treatment. The primary outcomes measured were changes in peak systolic velocity (PSV), end diastolic velocity (EDV), and resistive index (RI) after CCH treatment. Paired t-Tests were performed to determine statistical significance (P<0.05).
RESULTS: A total of 24 patients were included in the study, of which 20 (83%) completed four cycles of treatment (consisting of eight total injections) and 4 completed three cycles. After 3-4 cycles of CCH therapy, there was no statistically significant change in EDV, RI, or International Index of Erectile Function (IIEF) score when compared to baseline. PSV, however, improved significantly from 48.4AE11.9 cm/s at baseline to 52AE10.9 cm/s (p<0.05) after CCH therapy. There was also a statistically significant change in penile curvature (56.5AE18.7 to 34.7AE18.1 , p<0.001) and erect penile circumference (11.5AE1.2 cm to 11.9AE1.3 cm, p<0.05) after treatment.
CONCLUSIONS: In spite of a significant change in penile curvature, this change did not correlate with changing penile vascular parameters. There was a significant increase in PSV after completion of CCH therapy, although this change did not translate into improved subjective erectile function. However, as suggested by the lack of change in EDV and RI before and after treatment, as well as the absence of any clinical correlation with PSV, EDV, or RI, CCH therapy likely has a negligible impact on penile vasculature, further supporting a favorable safety profile of CCH. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e755

